Mirova Takes Position in Gilead Sciences, Inc. $GILD

Mirova bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 2,895 shares of the biopharmaceutical company’s stock, valued at approximately $324,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Northern Trust Corp raised its position in shares of Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after purchasing an additional 2,458,954 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Gilead Sciences by 15.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,234,672 shares of the biopharmaceutical company’s stock worth $1,130,117,000 after buying an additional 1,605,730 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Gilead Sciences by 30.1% during the fourth quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company’s stock valued at $801,655,000 after acquiring an additional 2,005,863 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.2%

Shares of GILD stock opened at $114.77 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $75.91 and a twelve month high of $121.83. The company’s 50-day moving average price is $112.51 and its 200-day moving average price is $109.08. The stock has a market cap of $142.41 billion, a price-to-earnings ratio of 22.86, a PEG ratio of 0.70 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GILD. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a report on Friday, August 8th. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Finally, UBS Group upped their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $115.39.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the sale, the chief executive officer owned 605,725 shares in the company, valued at $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,339,230 in the last three months. 0.27% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.